3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
153
Lung Neoplasms
69
Carcinoma, Hepatocellular
63
Small Cell Lung Carcinoma
48
Breast Neoplasms
47
Squamous Cell Carcinoma of Head and Neck
35
Urinary Bladder Neoplasms
30
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Neoplasms
28
Neoplasm Metastasis
28
Cholangiocarcinoma
26
Triple Negative Breast Neoplasms
25
Pancreatic Neoplasms
25
Ovarian Neoplasms
24
Liver Neoplasms
18
Head and Neck Neoplasms
18
Carcinoma, Renal Cell
17
Recurrence
16
Melanoma
14
Stomach Neoplasms
13
Prostatic Neoplasms
13
Carcinoma
13
Endometrial Neoplasms
12
Uterine Cervical Neoplasms
11
Esophageal Neoplasms
11
Carcinoma, Transitional Cell
11
Lymphoma, Large B-Cell, Diffuse
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Interventions
Irinotecan
10
Fluorouracil
10
Leucovorin
9
Bevacizumab
9
Gemcitabine
8
Paclitaxel
7
Cisplatin
7
Capecitabine
7
Oxaliplatin
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Sorafenib
4
Cetuximab
4
pembrolizumab
3
apatinib
3
Radiotherapy
3
Ocoxin
3
Imatinib Mesylate
3
Folfox protocol
3
Everolimus
3
Drug Therapy
3
tislelizumab
2
spartalizumab
2
palbociclib
2
entinostat
2
encorafenib
2
camrelizumab
2
anlotinib
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Digestive System Neoplasms
×
durvalumab
×
Clear all
NCT05063565
2026-04-29
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled